Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens

Ting Yi Chen, Mamta K. Jain

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Hepatitis C (HCV)-related liver disease has become one of the leading causes of death in HIV patients. With the development of new direct-acting antivirals for HCV, treatment regimens have become shorter, more effective, and easier to tolerate without interferon. However, cost may be a significant impediment to the widespread use of these newer agents in both resource-rich and resource-poor settings. In HIV patients, treatment for HCV is not always as straightforward compared with HCV monoinfected patients due to potential drug-drug interactions. In this article, we will examine by genotypes the FDA approved direct-acting antivirals, as well as those in clinical trials that will soon be FDA-approved focusing on data in HCV/HIV co-infection. Preferred agents for HCV treatment and potential drug-drug interactions with antiretroviral therapy (ART) will be highlighted.

Original languageEnglish (US)
Pages (from-to)329-337
Number of pages9
JournalAIDS Patient Care and STDs
Issue number6
StatePublished - Jun 1 2015

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens'. Together they form a unique fingerprint.

Cite this